Fmr LLC Has $519.17 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

FMR LLC grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 36.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,471,405 shares of the biotechnology company's stock after acquiring an additional 393,777 shares during the period. FMR LLC owned about 3.30% of United Therapeutics worth $519,170,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Wealthfront Advisers LLC boosted its position in shares of United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after buying an additional 18,313,424 shares in the last quarter. Norges Bank purchased a new position in United Therapeutics during the fourth quarter worth $151,764,000. Thrivent Financial for Lutherans raised its holdings in shares of United Therapeutics by 1,325.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company's stock worth $72,085,000 after acquiring an additional 189,967 shares during the last quarter. AustralianSuper Pty Ltd boosted its stake in shares of United Therapeutics by 577.1% during the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company's stock valued at $66,962,000 after acquiring an additional 161,751 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in United Therapeutics by 28.5% during the 4th quarter. Alliancebernstein L.P. now owns 709,043 shares of the biotechnology company's stock worth $250,179,000 after purchasing an additional 157,363 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Down 0.3 %

Shares of UTHR traded down $0.84 during trading on Tuesday, reaching $283.47. The company's stock had a trading volume of 145,467 shares, compared to its average volume of 463,022. United Therapeutics Co. has a twelve month low of $230.39 and a twelve month high of $417.82. The company has a market cap of $12.73 billion, a price-to-earnings ratio of 12.45, a P/E/G ratio of 0.97 and a beta of 0.63. The company has a fifty day moving average of $321.83 and a two-hundred day moving average of $350.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same quarter last year, the firm earned $4.36 EPS. As a group, equities analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now owns 8,480 shares of the company's stock, valued at $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Raymond Dwek sold 4,000 shares of United Therapeutics stock in a transaction on Monday, April 7th. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00. Following the transaction, the director now owns 1,750 shares in the company, valued at approximately $497,962.50. This trade represents a 69.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 77,500 shares of company stock worth $26,994,480. 11.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on UTHR shares. HC Wainwright reissued a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. Finally, UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.